Prognosis significance of p-mTOR expression in gastric cancer

doi:10.3877/cma.j.issn.1674-0793.2009.06.012

Abstract

Abstract:

Objective

To investigate the prognostic significance of activated mTOR(p-mTOR)expression in gastric cancer patients undergoing curative surgery.

Methods

The expression of p-mTOR was detected in specimens of 181 gastric cancers who underwent radical resection(R0)by immunohistochemistry.The influence of each variable on survival was analyzed by the multivariate analysis of Cox proportional hazard model.

Results

The positive rate of p-mTOR in gastric cancer was 51.4%. Patients with p-mTOR positive showed significantly shorter disease-free survival(DFS)and overall survival(OS)rates than those with p-mTOR-negative tumors in univariate analyses (DFS,P<0.01 and OS,P<0.05,respectively),and there was a trend toward a correlation between p-mTOR expression and survival in multivariate analyses (DFS, P=0.059 and OS,P=0.07,respectively).

Conclusion

The expression of mTOR actived is associated with poor prognosis in patients with gastric cancer underwentcurative surgery.

Key words: Gastric cancer, p-mTOR, Immunohistochemistry

Da-zhi XU, Jing-hui HOU, You-qing ZHAN, Zhi-wei ZHOU, Wei LI, Ying-bo CHEN, Xiao-wei SUN, Yuan-xiang GUAN, Yuan-fang LI, Tong-yu LIN. Prognosis significance of p-mTOR expression in gastric cancer[J]. Chinese Archives of General Surgery(Electronic Edition), 2009, 03(06): 495-498.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2009.06.012

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2009/V03/I06/495

Figures/Tables 5

References 12

1	Lieto E, Ferraraccio F, Orditura M, et al. Expression of vascular endothelial growth factor(VEGF) and epidermal growth factor receptor(EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients.Ann Surg Oncol，2008，15(1):69-79.
2	Galizia G,Lieto E,Orditura M,et al.Epidermal growth factor receptor(EGFR)expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery.World J Surg,2007,31(7):1458-1468.
3	Wang KL,Wu TT,Choi IS,et al.Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas:association with poor outcome.Cancer，2007,109(4):658-667.
4	Meric-Bernstam F,Gonzalez-Angulo AM.Targeting the mTOR signaling network for cancer therapy.J Clin Oncol，2009，27(13):2278-2287.
5	KinkadeCW,Castillo-MartinM,PuzioA,etal.TargetingAKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model.J Clin Invest,2008,118(9):3051-64.
6	Dasanu CA,Clark BA 3rd,Alexandrescu DT.mTOR-blocking agents in advanced renal cancer:an emerging therapeutic option.Expert Opin Investing Drugs,2009,18(2):175-187.
7	Marinov M, Ziogas A, Pardo OE, et al. AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001.Clin Cancer Res，2009，15(4):12 77-1287.
8	Noh WC, Kim YH, Kim MS, et al. Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables.Breast Cancer Res Treat，2008，110(3):477-483.
9	Beata Herberger, Harald Puhalla, Martina Lehnert, et al. Activated Mammalian Target of Rapamycin Is an Adverse Prognostic Factor in Patients with Biliary Tract Adenocarcinoma.Clin Cancer Res，2007，13(16):4795-4799.
10	Bjornsti MA,Houghton PJ.The TOR pathway:a target for cancer the rapy.Nat Rev Cancer,2004,4(5):335-348.
11	Yu G,Wang J,Chen Y,et al.Over expression of phosphorylated mam malian target of rapamycin predicts lymph node metastasis and prognosis of Chinese patients with gastric cancer.Clin Cancer Res,2009,15(5):1821-1829.
12	Murayama T,Inokuchi M,Takagi Y,et al.Relation between outcomes and localization of p-mTOR expression in gastric cancer.Br J Cancer，2009，100(5):782-788.

项目	例数	无病生存率			总生存率
项目	例数	ＨＲ	95% CI	P	HR	95% CI	P
年龄（岁）				0.343			0.583
＜60	95	1.00			1.00
≥60	86	0.834	0.573～1.214		0.898	0.611～1.320
性别				0.662			0.950
男	129	1.00			1.00
女	52	0.909	0.591～1.396		0.986	0.639～1.521
肿瘤大小(cm)				0.151			0.232
≤4	63	1.00			1.00
＞4	118	1.345	0.897～2.016		1.287	0.851～1.945
pT分期				0.001			0.005
pT1	17	1.00			1.00
pT2	35	1.549	0.558～4.301	0.401	1.535	0.553～4.264	0.411
pT3	119	3.546	1.437～8.750	0.006	3.237	1.310～8.001	0.011
pT4	10	4.738	1.547～14.506	0.006	4.068	1.289～12.836	0.017
pN状况				＜0.0001			0.001
阴性	44	1.00			1.00
阳性	137	2.617	1.538～4.451		2.389	1.401～4.075
p-mTOR表达				0.008			0.013
阴性	88	1.00			1.00
阳性	93	1.667	1.146～2.454		1.644	1.112～2.430

项目	例数	无病生存率			总生存率
项目	例数	ＨＲ	95% CI	P	HR	95% CI	P
年龄（岁）				0.343			0.583
＜60	95	1.00			1.00
≥60	86	0.834	0.573～1.214		0.898	0.611～1.320
性别				0.662			0.950
男	129	1.00			1.00
女	52	0.909	0.591～1.396		0.986	0.639～1.521
肿瘤大小(cm)				0.151			0.232
≤4	63	1.00			1.00
＞4	118	1.345	0.897～2.016		1.287	0.851～1.945
pT分期				0.001			0.005
pT1	17	1.00			1.00
pT2	35	1.549	0.558～4.301	0.401	1.535	0.553～4.264	0.411
pT3	119	3.546	1.437～8.750	0.006	3.237	1.310～8.001	0.011
pT4	10	4.738	1.547～14.506	0.006	4.068	1.289～12.836	0.017
pN状况				＜0.0001			0.001
阴性	44	1.00			1.00
阳性	137	2.617	1.538～4.451		2.389	1.401～4.075
p-mTOR表达				0.008			0.013
阴性	88	1.00			1.00
阳性	93	1.667	1.146～2.454		1.644	1.112～2.430

项目	例数	无病生存时间			总生存时间
项目	例数	HR	95% CI	P	HR	95% CI	P
p-mTOR表达				0.059			0.070
阴性	88	1.00			1.00
阳性	93	1.452	0.986～2.138		1.443	0.970～2.147
PT分期				0.018			0.046
pT1	17	1.00			1.00
pT2	35	1.050	0.366～3.016	0.928	1.078	0.375～3.101	0.889
pT3	119	2.251	0.867～5.845	0.096	2.146	0.823～5.595	0.118
pT4	10	2.926	0.920～9.305	0.069	2.616	2.616～8.580	0.113
淋巴结转移				0.018			0.038
有	44	1.00			1.00
无	137	1.981	1.981～3.488		1.828	1.034～3.233

项目	例数	无病生存时间			总生存时间
项目	例数	HR	95% CI	P	HR	95% CI	P
p-mTOR表达				0.059			0.070
阴性	88	1.00			1.00
阳性	93	1.452	0.986～2.138		1.443	0.970～2.147
PT分期				0.018			0.046
pT1	17	1.00			1.00
pT2	35	1.050	0.366～3.016	0.928	1.078	0.375～3.101	0.889
pT3	119	2.251	0.867～5.845	0.096	2.146	0.823～5.595	0.118
pT4	10	2.926	0.920～9.305	0.069	2.616	2.616～8.580	0.113
淋巴结转移				0.018			0.038
有	44	1.00			1.00
无	137	1.981	1.981～3.488		1.828	1.034～3.233

[1]	Yang Zhao, Yingcong Xiao, Yan Ju, Xiaozhi Dang, Linli Cai, Wenxin Xue, Yang Li, Yao Xiao, Yuqi Guo, Hongping Song. Clinical value of automated breast ultrasound combined with immunohistochemistry in early prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(04): 361-369.
[2]	Huajuan Shen, Jianbo Zhuang, Chun Liu. Correlation between Helicobacter pylori infection antibody typing and the severity of gastric mucosal inflammatory lesions and mucosal histological changes [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2024, 18(03): 156-162.
[3]	Yifang Chen, Xiaohui Huang. Expression and clinical significance of paraoxonase 2 in hepatocellular carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(03): 186-191.
[4]	Ningning Hu, Yanrong Zhao, Dong Wang, Shengliang Wang, Yuan Guo. The correlation study between the expression of FMNL3 and prognosis in hepatocellular carcinoma liver transplant recipients [J]. Chinese Journal of Transplantation(Electronic Edition), 2024, 18(05): 283-288.
[5]	Qinliang Si, Shilong Bi, Huixiao Jiao, Shizhao Li, Zheyu Chen, Yudong Wu. Two cases of dedifferentiated liposarcoma of spermatic cord and literature review [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(06): 585-590.
[6]	Peng Wang, Xinxin Shao, Haitao Hu, Yantao Tian, Yuxin Zhong. Application of modified MOBS anastomosis in total laparoscopic proximal gastrectomy [J]. Chinese Journal of Laparoscopic Surgery(Electronic Edition), 2024, 17(05): 267-270.
[7]	Haitao Hu, Xinxin Shao, Yujuan Jiang, Peng Wang, Weikun Li, Yiming Lu, Yantao Tian. The impact of duodenal stump management on postoperative complications following totally laparoscopic gastrectomy for gastric cancer [J]. Chinese Journal of Laparoscopic Surgery(Electronic Edition), 2024, 17(04): 205-209.
[8]	Zeqin Wang, Jun Hong, Yaping Wang, Jian Wang, Hankun Hao. The application of W-shaped liver suspension technique in totally laparoscopic total gastrectomy [J]. Chinese Journal of Laparoscopic Surgery(Electronic Edition), 2024, 17(04): 218-221.
[9]	Xianyong Liu, Dongmei Qin, Ruomei Zhang, Junjiao Li, Chunqin Meng, Mingxin Wu, Yuhong Wang, Xinxian Zhao, Ruilian Xv, Wenwen Hong, Ling Ma, Wei Qiu, Yu Zhou. Expression and significance of Her2/Hes1 in three pathological stages of Correa cascade in intestinal gastric cancer [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2024, 14(06): 321-327.
[10]	Jing Li, Xia Pan, Fang Zhou, Jing Wang, Jia Hong. Procaine inhibits the proliferation, migration and invasion of gastric cancer cells through up-regulating lncRNA DGCR5 [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2024, 14(03): 151-158.
[11]	Xi Gan, Xin Liao. Correlation analysis of tumor deposition near gastric cancer with CT imaging characteristics, serum indexes and pathological characteristics [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(05): 422-425.
[12]	Letian Yuan, Yilin Wang, Zijian Shen, Chengxin Yan. Diagnostic values of serum GDF15, sB7-H1 combined with multi-slice spiral CT perfusion imaging technology for lymph node metastasis in gastric cancer patients [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(01): 62-66.
[13]	Xuemei Ge. Efficacy and safety of SOX and mFOLFOX6 chemotherapy regimen for advanced gastric cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(01): 67-71.
[14]	Ruiyi Tan. Current advances and developments in diagnosis and treatment of small cell osteosarcoma [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(08): 781-784.
[15]	Binyan Guo, Yanliu Chu. Research status and prospect of staging evaluation model for gastric cancer [J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2024, 11(02): 120-122.

Please choose a citation manager

Content to export